Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy: results from an observational study

Abstract

Aim: Cardiovascular disease is a leading cause of mortality among long-term cancer survivors treated with large total doses of doxorubicin. An increase in coronary artery disease (CAD) among childhood cancer survivors by age 45 has been observed and is driven by primarily anthracycline chemotherapy and to a lesser extent chest radiation that includes the heart in the radiation field. The risk factors and associated chronic diseases (hypertension, etc.) are well known for CAD and can be often prevented or treated, thus reducing the risk of CAD in these patients. We piloted a risk-based survivorship clinic in an academic medical center to characterize the distribution of risk factors for CAD and improve the quality of life in a population of sarcoma survivors treated with doxorubicin.

Methods: We followed a prospective cohort of sixty-one survivors of bone and soft tissue sarcoma treated with doxorubicin chemotherapy (> 400 mg/m²) and at least 2 years post-therapy attending the sarcoma survivorship clinic. We collected clinical, demographic data, and patient reported outcomes via PROMIS questionnaires annually.

Results: We demonstrated a high burden of chronic diseases in this population. Among six chronic conditions that are known risk factors for CAD (hypertension, diabetes, obesity, chronic inflammation, kidney disease and dyslipidemia), more than one-fourth (26%, 16/61) of patients had three or more of these risk factors at baseline visit, and 49% (30/61) had two or more.

Conclusion: The results of this pilot study support the presence of modifiable CAD risk factors in this population of sarcoma survivors. Evidence-based guidelines for high-risk survivors of rare cancers are needed.

Keywords

Coronary artery disease / cardiovascular disease / sarcoma / anthracycline / cancer survivor

References

[1] O’Bryan RM,Talley RW,Baker LH.Phase II evaluation of adriamycin in human neoplasia..Cancer1973;32:1-8

[2] Benjamin RS,Bachur NR.Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule..Cancer1974;33:19-27

[3] Von Hoff DD,Layard M,Muggia FM.Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases..Am J Med1977;62:200-8

[4] Zalupski M,Balcerzak S,Chapman R.Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study..J Natl Cancer Inst1991;83:926-32

[5] Oeffinger KC,Sklar CA,Hudson MM.Chronic health conditions in adult survivors of childhood cancer..N Engl J Med2006;355:1572-82

[6] Armstrong GT,Yasui Y,Leisenring W.Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study..J Clin Oncol2009;27:2328-38 PMCID:PMC2677921

[7] Armenian SH,Aune G,Ehrhardt MJ.Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention..J Clin Oncol2018;36:2135-44 PMCID:PMC6804893

[8] Gibson TM,Stratton KL,Barnea D.Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort..Lancet Oncol2018;19:1590-601 PMCID:PMC6309183

[9] Bagnasco F,Andreano A,Jankovic M.Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry..Eur J Cancer2019;110:86-97

[10] Chatterjee K,Honbo N.Doxorubicin cardiomyopathy..Cardiology2010;115:155-62 PMCID:PMC2848530

[11] Rosenberg SA,Lawrence TS.2015;11th ed.Lippincott, Williams & Wilkins

[12] Chow EJ,Hudson MM,Kremer LC.Prediction of ischemic heart disease and stroke in survivors of childhood cancer..J Clin Oncol2018;36:44-52 PMCID:PMC5756324

[13] Armstrong GT,Chen Y,Yasui Y.Modifiable risk factors and major cardiac events among adult survivors of childhood cancer..J Clin Oncol2013;31:3673-80 PMCID:PMC3804290

[14] Ridker PM,Thuren T,Chang WH.Antiinflammatory therapy with canakinumab for atherosclerotic disease..N Engl J Med2017;377:1119-31

[15] Chen Y,Oeffinger KC,Leisenring WM.Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors..J Natl Cancer Inst2020;112:256-65 PMCID:PMC7073918

[16] Blaes AH.Is it time to include cancer in cardiovascular risk prediction tools?.Lancet2019;394:986-8

[17] Ridker PM,Everett BM,Thuren T.Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial..Lancet2018;391:319-28

[18] Ridker PM,Thuren T,Libby P.Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial..Lancet2017;390:1833-42

[19] Arnett DK,Albert MA,Goldberger ZD.2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines..J Am Coll Cardiol2019;74:1376-414

[20] Grundy SM,Bailey AL,Birtcher KK.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines..Circulation2019;139:e1082-143 PMCID:PMC7403606

[21] Ganz PA.Ganz PA.Breast cancer survivorship: where are we today?.Improving Outcomes for Breast Cancer Survivors: Perspectives on Research Challenges and Opportunities.2015;ChamSpringer International Publishing1-8

[22] Jacobs LA.Follow-up care of cancer survivors: challenges and solutions..Lancet Oncol2017;18:e19-29

[23] Rokitka DA,Heffler JE,Attwood K.Patterns of loss to follow-up care among childhood cancer survivors..J Adolesc Young Adult Oncol2017;6:67-73 PMCID:PMC5824664

[24] Suh E,Wroblewski K,Kigin ML.General internists’ preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey..An Intern Med2014;160:11-7 PMCID:PMC4337806

[25] Nathan PC,Wroblewski KE,Stewart TV.Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer..J cancer Surviv2013;7:275-82

[26] Bobowski NP.The university of michigan sarcoma survivorship clinic: preventing, diagnosing, and treating chronic illness for improved survival and long-term health..J Adolesc Young Adult Oncol2016;5:211-4 PMCID:PMC5076479

[27] D’Agostino RB,Pencina MJ,Cobain M.General cardiovascular risk profile for use in primary care: the framingham heart study..Circulation2008;117:743-53

[28] Ridker PM,Rifai N,Cook NR.C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men..Circulation2008;118:2243-51 PMCID:PMC2752381

[29] Orimoloye OA,Uddin SMI,Miedema MD.Association between self-rated health, coronary artery calcium scores, and atherosclerotic cardiovascular disease risk: the multi-ethnic study of atherosclerosis (MESA)..JAMA Netw Open2019;2:e188023 PMCID:PMC6484585

[30] Harris PA,Thielke R,Gonzalez N.Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support..J Biomed Inform2009;42:377-81 PMCID:PMC2700030

[31] Armenian SH,Ky B,Farol LT.Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study..J Clin Oncol2016;34:1122-30 PMCID:PMC7357493

[32] Bhagat A.The role of the innate immune system in doxorubicin-induced cardiotoxicity..Am Assoc Immnol2019;202:187.16